N-Terminal Fragment of Brain-Type Natriuretic Peptide (NT-proBNP) as a Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Prognostic value of N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) was analyzed in patients with multiple myeloma complicated by dialysisdependent renal failure. The prospective study included 20 patients with newly diagnosed multiple myeloma. The concentrations of NT-proBNP were measured before antimyeloma chemotherapy. The median age of the patients was 67 (63-76) years. The median glomerular filtration rate was 4 (4, 5) ml/min/1.73 m2. For overall survival, the area under ROC curve was 0.75 and the cut-off point was 7000 pg/ml. At median follow-up of 17.3 months, the overall survival was 76.6±14.8 and 27.3±13.4% (p=0.02) for cases with NT-proBNP levels below and above the cut-off point, respectively. There were no cases of death due to cardiovascular causes. We concluded that the increase in serum concentration of NT-proBNP>7400 pg/ml is associated with the severity of kidney damage and the risk of non-cardiac mortality.

作者简介

S. Semochkin

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation; N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow; Moscow

E. Misyurina

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

E. Zhelnova

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

E. Yurova

N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

D. Gagloeva

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

N. Aref’eva

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

A. Ushakova

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

O. Kotenko

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

T. Tolstykh

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

D. Sinyavkin

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

E. Baryakh

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation; N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow; Moscow

K. Yatskov

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

I. Samsonova

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow

M. Lysenko

Municipal Clinical Hospital No. 52, Moscow Healthcare Department, Ministry of Health of the Russian Federation

Email: semochkin_sv@rsmu.ru
俄罗斯联邦, Moscow


版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2019
##common.cookie##